ライフサイエンスコーパス: intravitreal injection

1 re identified to have RRD within 3 months of intravitreal injection.

2 of first injection and frequency interval of intravitreal injection.

3 ment with HORV 1 to 21 days after surgery or intravitreal injection.

4 mediate transduction following noninvasive, intravitreal injection.

5 d RGCs into uninjured rat retinas in vivo by intravitreal injection.

6 vides opportunities for dosing routes beyond intravitreal injection.

7 but potentially devastating complication of intravitreal injection.

8 al allergic reactions or complications after intravitreal injection.

9 atients diagnosed with DME who had undergone intravitreal injection.

10 factors for RRD may predispose to RRD after intravitreal injection.

11 gain with less incidence of recurrence than intravitreal injection.

12 treal injections (0.0084%) within 90 days of intravitreal injection.

13 owing increase in intraocular pressure by an intravitreal injection.

14 the DVC and a poor anatomical response after intravitreal injection.

15 IOP were detected in either group after the intravitreal injection.

16 g through an undilated pupil followed by the intravitreal injection.

17 ficantly associated with cyst response after intravitreal injection.

18 almitis is rare and seen most commonly after intravitreal injections.

19 h endophthalmitis after cataract surgery and intravitreal injections.

20 ed, including prior occurrence and number of intravitreal injections.

21 rgoing cataract surgery after multiple prior intravitreal injections.

22 surgery for beneficiaries with a history of intravitreal injections.

23 ng optical coherence tomography (OCT)-guided intravitreal injections.

24 d by anti-vascular endothelial growth factor intravitreal injections.

25 her countries using different techniques for intravitreal injections.

26 ve ranibizumab 0.5 mg or bevacizumab 1.25 mg intravitreal injections.

27 omplete resolution of fluid despite multiple intravitreal injections.

28 One patient underwent bilateral intravitreal injections.

29 antibioprophylaxis remains controversial in intravitreal injections.

30 ographics, visual acuity (VA), and number of intravitreal injections.

31 with patient face mask use during simulated intravitreal injections.

32 group included 147 fellow eyes with no prior intravitreal injections.

33 outine VA assessment, DFEs, OCT imaging, and intravitreal injections.

34 program and for patients receiving anti-VEGF intravitreal injections.

35 but a no-talking policy was observed during intravitreal injections.

36 inclusion criteria, receiving 26.4 +/- 15.9 intravitreal injections.

37 ated RRDs, giving a rate of 1 RRD per 11 941 intravitreal injections (0.0084%) within 90 days of intr

38 r injection, giving a rate of 1 RRD per 7532 intravitreal injections (0.013%) and 1 RRD per 530 patie

39 ncomycin via intracameral bolus (33/36), via intravitreal injection (1/36), or through the irrigation

40 ), post-glaucoma implant (6/19, 31.6%), post-intravitreal injection (2/19, 10.5%), endogenous endopht

41 s listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2),

42 ts independently perform procedures, such as intravitreal injections (23.1%) and minor lid procedures

43 es), whereas the remaining were secondary to intravitreal injections (35 eyes [14.8%]), PPV (29 eyes

44 oth the first and second episodes was recent intravitreal injection (50% and 58.3%, respectively) fol

45 d by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92

46 both at baseline (73%) and following serial intravitreal injections (78%, P = .73).

47 Intravitreal injections accounted for 0.55% of all vitre

48 rts were created using information on 530382 intravitreal injections administered from January 1, 200

49 Of 483,622 intravitreal injections administered, 168 out of 453,460

50 Predictors of VA gain included number of intravitreal injections (AMD and PCV adjusted odds ratio

51 -up visits were performed 1 month after each intravitreal injection and included OCT analysis to eval

52 was 100% regression of vitreous seeds after intravitreal injection and no eye was treated with radia

53 ts when measured between 0 and 30 minutes of intravitreal injection and that the IOP elevation decrea

54 tion presented 4 weeks after his most recent intravitreal injection and was found to have endophthalm

55 Given the frequency of intravitreal injections and cataract surgery, increased

56 of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment eff

57 educed bacterial dispersion during simulated intravitreal injections and had no difference in bacteri

58 rate of FFS Medicare beneficiaries receiving intravitreal injections and the mean Medicare-allowed dr

59 rior anti-vascular endothelial growth factor intravitreal injections and were responsive to treatment

60 Intravitreal injections are a mandatory treatment for ma

61 Intravitreal injections are the most common treatment mo

62 Repeat analysis considering intravitreal injections as a categoric variable showed 1

63 By considering the number of previous intravitreal injections as a continuous variable, the od

64 iltrate cells in the EAU mice after a single intravitreal injection at the onset of peak disease.

65 accept a high treatment burden with regular intravitreal injections at short intervals and long peri

66 After intravitreal injection, bevacizumab can be detected in s

67 treal drug injection (3 eyes after the first intravitreal injection: bevacizumab in 1 and ranibizumab

68 Intravitreal injection can be given safely without pre-o

69 ory of RD or retinal break, endophthalmitis, intravitreal injection, choroidal retinal vitreal biopsy

70 d Medicaid Services was used to identify all intravitreal injection claims and anti-VEGF drug claims

71 assessment of the Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secon

72 uce longer-term local drug administration by intravitreal injection compared to previously reported d

73 Data were searched for all intravitreal injections (Current Procedural Terminology

74 the rate of RNFL thinning in eyes receiving intravitreal injections did not significantly differ fro

75 al superiority of 1-time therapy to repeated intravitreal injections due to reduction in adverse even

76 zumab to 0.5 mg ranibizumab given as monthly intravitreal injections during 6 months in patients with

77 ds are currently delivered inside the eye by intravitreal injection (e.g. Ozurdex(R), an intravitreal

78 rvice volume elasticity were nonsignificant: intravitreal injection elasticity, -0.75 (95% confidence

79 As in this case, post-intravitreal injection endophthalmitis may have a bacter

80 egeneration and diabetic retinopathy require intravitreal injections every 4-8 weeks.

81 NPV (88.6%-100%) including billing codes for intravitreal injection, focal laser, panretinal photocoa

82 A total of 5 patients (2.2%) received intravitreal injections following funduscopic screening.

83 elivery may become a safe alternative to the intravitreal injection for chronic retinal diseases such

84 D that occurred within 90 days of a previous intravitreal injection for nAMD.

85 An exact total of 203 000 intravitreal injections for nAMD were administered.

86 2, 2008 to June 30, 2013, a total of 316,576 intravitreal injections from 25 French ophthalmic center

87 dophthalmitis), our analysis involved 383810 intravitreal injections given to 58612 patients.

88 mber 2016, nonpriming the syringe before the intravitreal injection had a higher risk of intravitreal

89 Since 2015 our treatment scheme for intravitreal injections has been switched from PRN to TE

90 a combination of both, were administered by intravitreal injection immediately after laser injury.

91 luted when used as an antiseptic prior to an intravitreal injection in an attempt to decrease patient

92 preliminary efficacy of 125 mug ocriplasmin intravitreal injection in patients with focal vitreomacu

93 A total of 180 671 intravitreal injections in 12 718 unique patients were i

94 Intravitreal injections in eyes receiving multiple regul

95 gression analysis, over the course of weekly intravitreal injections in retinoblastoma patients, for

96 The review assessed 4488 intravitreal injections in the 3-month period before (Ma

97 Intravitreal injections increased by 89 563%.

98 rs for PCR were age, sex, number of previous intravitreal injections, indication for intravitreal the

99 model as well as local ocular suppression in intravitreal injection-induced AP activation model in mi

100 Intravitreal injection is associated with rare but poten

101 The incidence of endophthalmitis after intravitreal injection is low.

102 Although RRD after intravitreal injection is rare, prior retinal surgery an

103 Retinal detachment after intravitreal injection is uncommon, with a rate of appro

104 0-day rate of RRD in nAMD patients receiving intravitreal injections is low.

105 ism underlying IOP elevation associated with intravitreal injections is unknown.

106 Pain after an intravitreal injection (IVI) can last up to 7 days and n

107 Importantly, one intravitreal injection (IVI) of 25 pmol MTX increased el

108 In contrast, after 1 intravitreal injection (IVI) of antibiotics, the identif

109 ted macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.

110 The intravitreal injection (IVI) of pharmacologic agents is

111 A 100 uL intravitreal injection (IVI) of saline was given in one

112 uring cataract surgery in eyes with previous intravitreal injection (IVI).

113 Intravitreal injections (IVI) of anti-vascular endotheli

114 remarkable improvement was noticed after the intravitreal injection(IVI) of Ozurdex, consistent with

115 AIDs) for the reduction of ocular pain after intravitreal injections (IVIs) has been explored.

116 ely used as an ocular surface antiseptic for intravitreal injections (IVIs).

117 e material available to the public regarding intravitreal injections (IVIs).

118 rofile during treatment, number of antiviral intravitreal injections (IVT), retinal detachment rate,

119 ious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothel

120 mab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfec

121 Intravitreal injections may be a precipitating factor fo

122 A history of intravitreal injections may be a risk factor for catarac

123 The cumulative number of intravitreal injections may be an independent risk facto

124 n monthly or every other month (EOM) or sham intravitreal injections monthly or EOM for 12 months wit

125 gs were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract

126 ionship between IOP increase and the type of intravitreal injection, number of intravitreal injection

127 us disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab.

128 The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept.

129 42 eyes), 1 eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow

130 One eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow

131 Intravitreal injection of 2-ME (in the two concentration

132 ose of study was to evaluate the efficacy of intravitreal injection of 2-Methoxyestradiol (2-ME) nano

133 Intravitreal injection of 2-Methoxyestradiol nanoemulsio

134 n of NIU, naive Lewis rats received a single intravitreal injection of AAV particles harboring codon-

135 e targeted ocular tissues following a single intravitreal injection of AAV-HLA-G1/5 significantly dec

136 spective open-label, unilateral single-dose, intravitreal injection of AAV2(Y444,500,730F)-P1ND4v2 pe

137 xygen-induced retinopathy resulting from the intravitreal injection of adipose Myh11-derived mesenchy

138 a suprachoroidal injection of CLS-TA with an intravitreal injection of aflibercept (combination arm)

139 of aflibercept (combination arm) or only an intravitreal injection of aflibercept (monotherapy arm),

140 Both intravitreal injection of aflibercept followed by PRP an

141 Intravitreal injection of aflibercept suppressed the aqu

142 Patients who developed endophthalmitis after intravitreal injection of aflibercept, bevacizumab, or r

143 It was further demonstrated that intravitreal injection of an MCP-1-neutralizing antibody

144 Intravitreal injection of anti-VEGF agents results in an

145 Following endophthalmitis from intravitreal injection of anti-VEGF agents, vitreous cul

146 Transient elevation in IOP is common after intravitreal injection of anti-VEGF agents.

147 Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and

148 53) underwent initial bedside aspirate with intravitreal injection of antibiotics (tap-and-injection

149 initial treatment was a vitreous culture and intravitreal injection of antibiotics in 28 of 36 patien

150 then treated either with a vitreous tap and intravitreal injection of antibiotics or with pars plana

151 in the proportion of eyes requiring a second intravitreal injection of antibiotics whether the eye wa

152 four disc areas, pars plana vitrectomy with intravitreal injection of antibiotics without retinectom

153 Eyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n = 182)

154 odds of developing endophthalmitis after an intravitreal injection of bevacizumab compared with rani

155 Initial treatment with either a single intravitreal injection of bevacizumab in off-label use (

156 ndividual from this data set who received an intravitreal injection of bevacizumab or ranibizumab (n=

157 outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with fellow eyes t

158 Eyes were randomly assigned to receive an intravitreal injection of bevacizumab, 1.25 mg, or aflib

159 Initial management included cryotherapy, intravitreal injection of bevacizumab, plaque radiothera

160 A pars plana vitrectomy with intravitreal injection of ceftazidime (2 mg/0.1 ml) and

161 In summary, the combination of intravitreal injection of conbercept and PRP can signifi

162 ents which responded well to intravenous and intravitreal injection of corticosteroids.

163 the patient was treated with intravenous and intravitreal injection of corticosteroids.

164 were anesthetized and received a unilateral intravitreal injection of CtB.

165 Intravitreal injection of DAD restored retinal light res

166 C57BL/6J mice received an intravitreal injection of Edn2 or control vehicle to exa

167 rms in mice and found that both systemic and intravitreal injection of engineered AAV vectors resulte

168 Intravitreal injection of FH535 in swine also inhibited

169 Ocular toxicity studies revealed that intravitreal injection of griseofulvin in adult mice doe

170 Intravitreal injection of IL-4 and IL-10 ameliorated RPE

171 Trans-pars plana intravitreal injection of melphalan hydrochloride (40 mi

172 Intravitreal injection of miR200-b DNA NPs significantly

173 Patients were to receive a single intravitreal injection of MP0112 at doses ranging from 0

174 Furthermore, a single intravitreal injection of MT-I/II after optic nerve crus

175 Intravitreal injection of neutralizing antibodies agains

176 Patients were treated with a single intravitreal injection of Ocriplasmin (Jetrea, Thromboge

177 A single intravitreal injection of ocriplasmin 125 mug or placebo

178 In clinical practice, intravitreal injection of ocriplasmin achieved VMT relea

179 Eyes were randomized to either a single intravitreal injection of ocriplasmin or placebo treatme

180 Intravitreal injection of Ocriplasmin resulted to be a s

181 If intravitreal injection of ocriplasmin was the primary pr

182 TG-MV-007, respectively) to receive a single intravitreal injection of ocriplasmin, 125 mug, or place

183 Patients received a single 0.125 mg intravitreal injection of ocriplasmin.

184 tored under control conditions and following intravitreal injection of pharmacological agents.

185 Intravitreal injection of platelet-derived growth factor

186 lopment of CNV which was treated by a single intravitreal injection of ranibizumab (0.5 mg/0.05 mL).

187 nths in comparison to standard therapy, i.e. intravitreal injection of ranibizumab alone.

188 A single intravitreal injection of ranibizumab had a long-lasting

189 Intravitreal injection of ranibizumab or bevacizumab.

190 All patients treated with intravitreal injection of ranibizumab, bevacizumab, or a

191 A single intravitreal injection of Ro5-3335 significantly decreas

192 Patients received a single intravitreal injection of RTH258 0.5 mg (n = 11), 3.0 mg

193 eanwhile, the RGC count was higher following intravitreal injection of SCH442416 in the COH rats than

194 Intravitreal injection of selective A2A AR antagonist SC

195 a typical case of AZOOR, suggesting that the intravitreal injection of steroid may benefit in certain

196 An intravitreal injection of the FECH inhibitor N-methyl pr

197 udy evaluated the efficacy and safety of the intravitreal injection of ziv-aflibercept in patients wi

198 diabetic macular edema (DME) received three intravitreal injections of 0.5 mg ranibizumab during the

199 igned randomly in a 2:2:1:1 ratio to receive intravitreal injections of 15 mg pegcetacoplan monthly o

200 ked criteria, for example, minimum number of intravitreal injections of a specific drug and visual ac

201 human clinical trials rely on subretinal or intravitreal injections of adeno-associated virus to del

202 Intravitreal injections of amikacin (0.4 mg/0.1 mL) were

203 NCT03140969 ) with intravitreal injections of an antisense oligonucleotide

204 was observed with ocular therapies including intravitreal injections of anti-vascular endothelial gro

205 Three patients were treated with 2.3 +/- 0.6 intravitreal injections of anti-vascular endothelial gro

206 incidence of presumed endophthalmitis after intravitreal injections of anti-vascular endothelial gro

207 All patients received at least 3 monthly intravitreal injections of anti-VEGF agents.

208 Neovascular AMD patients receiving intravitreal injections of anti-VEGF during the study pe

209 at these patients are less likely to receive intravitreal injections of anti-VEGF medication, laser t

210 Intravitreal injections of anti-VEGF medications increas

211 ntified anti-VEGF treatment using claims for intravitreal injections of anti-VEGF medications with a

212 ur study was to investigate whether repeated intravitreal injections of anti-VEGF would increase the

213 Vitreous cultures with intravitreal injections of antibiotics and pars plana vi

214 of ischemic optic neuropathy (ION) following intravitreal injections of antivascular endothelial grow

215 n intraocular pressure (IOP) associated with intravitreal injections of antivascular endothelial grow

216 al visual loss developed after they received intravitreal injections of autologous adipose tissue-der

217 From a total of 96 eyes treated with intravitreal injections of bevacizumab (10.5 +/- 7.6 (me

218 -control study between patients who received intravitreal injections of bevacizumab as the sole treat

219 Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in

220 All included patients had received intravitreal injections of bevacizumab, ranibizumab, or

221 der with diabetic macular edema who received intravitreal injections of bevacizumab.

222 Intravitreal injections of commonly used anti-VEGF intra

223 -3 study, patients with DME received monthly intravitreal injections of either 0.5 or 2.0 mg ranibizu

224 owering general retinal MMP activity through intravitreal injections of GM6001 after ONC strongly red

225 ocular hypertension (OHT), comparing single intravitreal injections of microspheres of DMQ-MSs to th

226 lt zebrafish of both sexes were subjected to intravitreal injections of ouabain, which destroys the i

227 Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg

228 tients were randomized 1:1 to receive either intravitreal injections of ranibizumab 0.5 mg or afliber

229 ar age-related macular degeneration received intravitreal injections of ranibizumab or bevacizumab un

230 atment-naive DME were treated with 3 monthly intravitreal injections of ranibizumab or bevacizumab.

231 Intravitreal injections of spironolactone-loaded microsp

232 ivery to the posterior eye segment relies on intravitreal injections of therapeutics.

233 Intravitreal injections of these peptides and PEDF in th

234 Intravitreal injections of triamcinolone obtained from a

235 aiiensis developed in a series of eyes after intravitreal injections of triamcinolone obtained from a

236 d for 15 patients (n = 17 eyes) who received intravitreal injections of triamcinolone obtained from a

237 s is a notice to ophthalmologists performing intravitreal injections of triamcinolone or other medica

238 Five patients were imaged before and after intravitreal injections of vascular endothelial growth f

239 DME is commonly treated with intravitreal injections of vascular endothelial growth f

240 The treatment involves monthly repeated intravitreal injections of VEGF inhibitors.

241 Effects of intravitreal injections of VEGF-A, VEGF-E, PlGF-1, and V

242 eovascular AMD diagnosis and mean numbers of intravitreal injections, ophthalmologist visits, and opt

243 andomized 3:1 to receive 125 mug ocriplasmin intravitreal injection or sham injection.

244 face masks were worn by the physician during intravitreal injections or "No Talking" group if no face

245 A single dose of SRT significantly reduces intravitreal injections over 2 years.

246 r NPDR, PDR, or DME or a procedural code for intravitreal injections, pars plana vitrectomy (PPV) or

247 ti-VEGF therapy, calculated as the number of intravitreal injections per month, and central macular t

248 g-term follow-up received significantly more intravitreal injections per year than eyes with inconsis

249 ce visits and received a mean of 5.8 +/- 2.5 intravitreal injections per year.

250 An audit of intravitreal injections performed by retinal specialists

251 he type of intravitreal injection, number of intravitreal injections, preexisting glaucoma, and globe

252 ioned at 20 cm in a simulated position of an intravitreal injection procedure.

253 es were surveyed regarding current anti-VEGF intravitreal injection protocols, including the anti-VEG

254 High variation was observed in intravitreal injection rates and in Medicare drug paymen

255 All patients who received subsequent intravitreal injections received PI prophylaxis without

256 outcomes in beneficiaries with a history of intravitreal injections relative to those without were c

257 ients undergoing OCT-guided retreatment with intravitreal injections resulted in decreased exposure t

258 A total of 792 intravitreal injection room surfaces were sampled (396 b

259 ing program reduced surface ATP bioburden in intravitreal injection rooms to less than clean benchmar

260 hich 1035 (1.64%) were in eyes with previous intravitreal injection(s).

261 (RNFL) thinning is faster in eyes receiving intravitreal injections than in fellow uninjected eyes a

262 ces in angle width associated with number of intravitreal injections that might explain this phenomen

263 patient refused oral corticosteroids and any intravitreal injection therapies.

264 metic Fab-PEG-Fab (FpFinfliximab) for direct intravitreal injection to assess whether such formulatio

265 ice-based MIVS, anti-VEGF, and dexamethasone intravitreal injections (triple therapy) for the treatme

266 re recommended in patients with a history of intravitreal injections undergoing cataract extraction.

267 We also evaluated the efficacy of intravitreal injection using a recently developed photor

268 .04 +/- 1.89 mum rendering them suitable for intravitreal injection using conventional 25G-32G needle

269 Ocular surface preparation for intravitreal injection using povidone-iodine 5% alone in

270 rate of FFS Medicare beneficiaries receiving intravitreal injections varied widely by 7-fold across s

271 tinuous variable, the odds ratio for PCR per intravitreal injection was 1.04 (P = 0.016) after adjust

272 After logistic regression, prior intravitreal injection was associated with an increased

273 en topical antibiotics were prescribed after intravitreal injection was compared with a 9-month perio

274 The suitability for ocriplasmin intravitreal injection was determined according to the c

275 The intravitreal injection was given by a single surgeon.

276 The mean number of intravitreal injections was 8.3 (range, 3-29 injections)

277 For each center, the number of intravitreal injections was determined using billing cod

278 mean (SEM) VAS pain scores immediately after intravitreal injection were 2.3 +/- 0.4 for patients rec

279 Additional risk factors for RRD other than intravitreal injection were present in 5 of 13 eyes (38%

280 Relative proportions of the drugs used for intravitreal injections were calculated and frequencies

281 g glaucoma in both eyes receiving unilateral intravitreal injections were identified.

282 During the study period, a total of 117 171 intravitreal injections were performed (57 654 injection

283 ,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 7

284 A total of 40 535 intravitreal injections were performed by 7 retinal spec

285 ess, treatment interval, and total number of intravitreal injections were secondary outcomes.

286 taract surgeon grade, and number of previous intravitreal injections were significant predictors of P

287 Intravitreal injections were the primary driver of growt

288 To mask both groups, sham suprachoroidal and intravitreal injections were utilized.

289 720 721 procedures [eg, surgery], and 45 416 intravitreal injections) were stored, including 81 274 o

290 udative form of the disease require repeated intravitreal injections which may be painful, are incomp

291 Current therapies require repeated intravitreal injections, which are painful and can cause

292 ving anti-vascular endothelial growth factor intravitreal injections, which transiently increase IOP.

293 reported cases of RRD in patients with prior intravitreal injection who underwent subsequent surgical

294 phthalmitis is a devastating complication of intravitreal injection with bevacizumab with a high rate

295 Intravitreal injection with the gene therapy vector AAV2

296 iseases usually need chronic treatment using intravitreal injections with anti-VEGF agents.

297 Patients were treated with intravitreal injections with bevacizumab; ranibizumab; o

298 Patients were assigned randomly to receive intravitreal injections with either ranibizumab 0.5 mg o

299 ti-vascular endothelial growth factor (VEGF) intravitreal injections without improvement.

300 The mean number of intravitreal injections without PI before the developmen